Practitioners Who Care for Patients with Migraine Diseases and Headache Disorders Should Review Updated Qualifications and Register by Feb. 23 The National Headache Foundation (NHF) announced its Spring certification exam for its Certificate of Added Qualification in Headache Medicine (AQH) program. The deadline for applying…
New Data Alert on the Up-and-Coming Migraine Medication: Intranasal Zavegepant. While not yet approved for release, intranasal zavegepant has shown promise in some interesting and unique data points in the relief of acute migraine. What is zavegepant and what will it offer us that is…
For the fourth consecutive year, the National Headache Foundation is raising funds on Giving Tuesday, November 30th, to provide support and resources to veterans and active-duty military living with migraine disease and headache disorders. The National Headache Foundation believes it is vital to reach out…
Getting sick is always an unwelcome disruption to our daily lives. Many of us use acetaminophen to treat our pain or fever symptoms—even if we don’t realize it. Acetaminophen is found in more than 600 over-the-counter (OTC) and prescription medicines. With COVID-19 still a part…
Did you know that tension headaches don’t really have anything to do with stress OR the muscles in your head? In this week’s episode of Heads Up, Dr. Lindsay Weitzel, Ph.D. talks with Dr. Vincent Martin, MD about the most common type of primary headache:…
Atogepant (QULIPTA) was just approved by the FDA as a daily oral preventive treatment for migraine. On this episode of Heads UP, Dr. Lindsay Weitzel asks migraine clinical trial expert Dr. Tim Smith all the hard questions: Can we take gepants like Nurtec or Ubrelvy…
The National Headache Foundation (NHF) welcomed 21 new healthcare providers who passed the recent certification exam for its Certificate of Added Qualification in Headache Medicine (AQH) program. Tom Dabertin, NHF chief executive officer and executive director, said “the September graduates have fully mastered the standards…
Headache Heroes 2021 Patient: Evie Mohan Advocate: Katie MacDonald Caregiver: Chris Charrett-Dykes Healthcare Provider: Jaclyn Duvall, MD, AQH Congratulations to the four Headache Heroes winners who were selected from the many nominations submitted by the public. The winners were honored at the National Headache Foundation’s…
The U.S. Food and Drug Administration (FDA) approved QULIPTA™ (atogepant) for the preventive treatment of episodic migraine in adults. QULIPTA is the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) specifically developed for the preventive treatment of migraine disease. The approval is…
The National Headache Foundation (NHF) launched Primary Care Migraine, a new educational training program available at no cost to health practitioners. The program was announced by Tom Dabertin, Executive Director and Chief Executive Officer of the National Headache Foundation. “NHF seeks to offer cutting-edge educational…
Subscribe to our Monthly e-Newsletter
Gain access to the most current migraine and headache information, prevention,
treatment, research, and news.
